Evidence map›Paper›PMID 39280256›Full record

ArticleDrug design, development and therapy2024

Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanism of Qushi Huatan Decoction Against Coronary Heart Disease.

Chunxia Yin, Taohua Lan, Yunshan Wu, Jing Cai, Haoxiang Li, Xiaolan Kuang, Lin Jiao, Xiaomin Ou, Hua Yang, Bo Liu and 1 more

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chunxia Yin *The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Taohua Lan *Department of Cardiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China.
Yunshan WuGuangzhou Key Laboratory of Chirality Research on Active Components of Traditional Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China.
Jing CaiThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Haoxiang LiThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Xiaolan KuangThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Lin JiaoThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Xiaomin OuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Hua YangDepartment of Cardiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China.
Bo LiuState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0000-0002-9539-2005
Weihui LuDepartment of Cardiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0000-0001-7754-2682

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study was designed to evaluate the effect and mechanism of the Qushi Huatan (QSHT) decoction against coronary heart disease (CHD) through network pharmacology and experimental verification. Methods: In the present study, the active ingredients of the QSHT decoction were identified by ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS), then the potential ingredients and coronary heart disease targets were predicted using the SwissTarget Prediction database and the database of Genecards and OMIM database, respectively. A herb-compound-target network was constructed using Cytoscape. GO and KEGG enrichment analysis were performed using the ClusterProfiler data package of R software. Molecular docking was used to predict the core targets of QSHT against CHD. In addition, we used a myocardial infarction (MI) and high-fat diet ApoE Results: A total of 68 active ingredients were found in the QSHT decoction. Network pharmacology indicated 28 targets and 147 signal pathways, including AKT1, HIF-1α, GSK-3β, TLR4 and NF-κB, those key targets were also verified by molecular docking. The results of GO and KEGG enrichment analysis showed that the targets of QSHT against CHD were largely associated with inflammatory and oxidative stress, and AKT/HIF-1α and TLR4/NF-κB pathways might be key functional pathways. In vivo, QSHT significantly improved cardiac function and attenuated fibrosis and inflammation. Furthermore, QSHT could significantly inhibit the expression of HIF-1α, TLR4, phosphorylation of AKT1, GSK-3β and NF-κB after MI in ApoE Conclusion: Based on network pharmacology, molecular docking and experimental verification, this study demonstrated that QSHT could improve cardiac function and attenuate cardiac fibrosis by regulating TLR4/NF-κB and AKT/HIF-1α signaling pathway in post- MI and high-fat diet ApoE

Indexed as

Coronary DiseaseDrugs, Chinese HerbalMolecular Docking SimulationNetwork PharmacologyAnimalsApolipoproteins EDiet, High-FatDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, KnockoutSignal TransductionTandem Mass SpectrometryApolipoproteins EDrugs, Chinese Herbalcoronary heart diseasemolecular dockingnetwork pharmacologyQushi Huatan decoction

Identifiers

PMID39280256
PMCPMC11402371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.